FDA moves to fast-track review of psilocybin and methylone for mental health

Some psychedelic drugs, once considered fringe, are now getting a step closer to possibly being approved for use as mental health treatments in the United States. The US Food and Drug Administration on Friday issued national priority vouchers to three companies studying these psychedelic-based medi...

Redirecting to full article...